Literature DB >> 30413841

Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease.

Reetta Kettunen1, Heidi Taipale2,3,4, Anna-Maija Tolppanen1,5, Antti Tanskanen6,7,8, Jari Tiihonen6,7, Sirpa Hartikainen1,9, Marjaana Koponen1,9.   

Abstract

PURPOSE: To study how long antidepressants initiated after diagnoses of Alzheimer's disease (AD) were used and factors associated with discontinuation of use among persons with Alzheimer's disease (AD). In addition, differences in duration of use between the antidepressants groups were compared.
METHODS: Register-based Medication use and Alzheimer's disease (MEDALZ) cohort included 70,718 community-dwelling people with AD who were diagnosed during the years 2005-2011. For this study, the new antidepressant users were included after 1-year washout period (N = 16,501; 68.6% females, mean age 80.9). The duration of antidepressant use was modeled with the PRE2DUP method. Factors associated with treatment discontinuation were assessed with Cox proportional hazard models and included age, gender, comorbid conditions and concomitant medications.
RESULTS: Median duration of the new antidepressant use period was 309 days (IQR 93-830). For selective serotonin reuptake inhibitor (SSRI) use, the median duration was 331 days (IQR 101-829), for mirtazapine 202 days (IQR 52-635), and for serotonin and norepinephrine reuptake inhibitors (SNRIs) 134 days (IQR 37-522). After 1-year follow-up, 40.8% had discontinued antidepressant use, 54.6% after 2 years and 64.1% after 3 years. Factors associated with treatment discontinuation were age over 85, male gender, diabetes, and use of memantine, opioids, and antiepileptics whereas benzodiazepines and related drugs and antipsychotic use were inversely associated with discontinuation.
CONCLUSIONS: Antidepressants are used for long-term among people with AD. Need and indication for antidepressant use should be assessed regularly as evidence on their efficacy for behavioral and psychological symptoms of dementia is limited.

Entities:  

Keywords:  Alzheimer’s disease; Antidepressants; Dementia; Discontinuation; Drug utilization; Persistence

Mesh:

Substances:

Year:  2018        PMID: 30413841     DOI: 10.1007/s00228-018-2591-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Evolution of the Antidepressant Prescribing in Alzheimer's Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer's Disease (BNA).

Authors:  Renaud David; Valeria Manera; Roxane Fabre; Christian Pradier; Philippe Robert; Karim Tifratene
Journal:  J Alzheimers Dis       Date:  2016-07-02       Impact factor: 4.472

3.  High prevalence of psychotropic drug use among persons with and without Alzheimer's disease in Finnish nationwide cohort.

Authors:  Heidi Taipale; Marjaana Koponen; Antti Tanskanen; Anna-Maija Tolppanen; Jari Tiihonen; Sirpa Hartikainen
Journal:  Eur Neuropsychopharmacol       Date:  2014-11       Impact factor: 4.600

4.  Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease.

Authors:  Sanna Torvinen-Kiiskinen; Anna-Maija Tolppanen; Marjaana Koponen; Antti Tanskanen; Jari Tiihonen; Sirpa Hartikainen; Heidi Taipale
Journal:  Int J Geriatr Psychiatry       Date:  2017-01-05       Impact factor: 3.485

5.  Use of antidepressants among community-dwelling persons with Alzheimer's disease: a nationwide register-based study.

Authors:  Marja-Liisa Laitinen; Eija Lönnroos; J Simon Bell; Piia Lavikainen; Raimo Sulkava; Sirpa Hartikainen
Journal:  Int Psychogeriatr       Date:  2014-11-21       Impact factor: 3.878

Review 6.  The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis.

Authors:  Marta M Maslej; Benjamin M Bolker; Marley J Russell; Keifer Eaton; Zachary Durisko; Steven D Hollon; G Marie Swanson; J Anderson Thomson; Benoit H Mulsant; Paul W Andrews
Journal:  Psychother Psychosom       Date:  2017-09-14       Impact factor: 17.659

7.  Antidepressant use and risk of adverse outcomes in older people: population based cohort study.

Authors:  Carol Coupland; Paula Dhiman; Richard Morriss; Antony Arthur; Garry Barton; Julia Hippisley-Cox
Journal:  BMJ       Date:  2011-08-02

Review 8.  Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis.

Authors:  Vasiliki Orgeta; Naji Tabet; Ramin Nilforooshan; Robert Howard
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Influences on antidepressant prescribing trends in the UK: 1995-2011.

Authors:  Becky Mars; Jon Heron; David Kessler; Neil M Davies; Richard M Martin; Kyla H Thomas; David Gunnell
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-11-24       Impact factor: 4.328

10.  Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.

Authors:  Jenna Wong; Aude Motulsky; Michal Abrahamowicz; Tewodros Eguale; David L Buckeridge; Robyn Tamblyn
Journal:  BMJ       Date:  2017-02-21
View more
  4 in total

Review 1.  A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.

Authors:  Mitzi M Gonzales; Sudarshan Krishnamurthy; Valentina Garbarino; Ali S Daeihagh; Gregory J Gillispie; Gagan Deep; Suzanne Craft; Miranda E Orr
Journal:  Mech Ageing Dev       Date:  2021-10-21       Impact factor: 5.498

2.  Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.

Authors:  Sube Banerjee; Juliet High; Susan Stirling; Lee Shepstone; Ann Marie Swart; Tanya Telling; Catherine Henderson; Clive Ballard; Peter Bentham; Alistair Burns; Nicolas Farina; Chris Fox; Paul Francis; Robert Howard; Martin Knapp; Iracema Leroi; Gill Livingston; Ramin Nilforooshan; Shirley Nurock; John O'Brien; Annabel Price; Alan J Thomas; Naji Tabet
Journal:  Lancet       Date:  2021-10-23       Impact factor: 79.321

3.  Gender Differences in Function, Physical Activity, Falls, Medication Use, and Life Satisfaction Among Residents in Assisted Living Settings.

Authors:  Barbara Resnick; Marie Boltz; Elizabeth Galik; Sarah Holmes; Steven Fix; Shijun Zhu
Journal:  Res Gerontol Nurs       Date:  2019-10-04       Impact factor: 1.571

4.  Identifying temporal patterns of adherence to antidepressants, bisphosphonates and statins, and associated patient factors.

Authors:  Kyu Hyung Park; Leonie Tickle; Henry Cutler
Journal:  SSM Popul Health       Date:  2021-11-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.